Research and analysis
Impact assessment opinion: Falsified Medicines Directive 2011/62/EU
- Regulatory Policy Committee
- Part of:
- Green and amber rated impact assessment opinions, RPC opinions on departmental impact assessments: published August 2014, and Business regulation
- First published:
- 27 August 2014
Evaluation of the Department of Health impact assessment for Falsified Medicines Directive 2011/62/EU
PDF, 70.5KB, 2 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email firstname.lastname@example.org. Please tell us what format you need. It will help us if you say what assistive technology you use.
The Regulatory Policy Committee (RPC) gives independent advice to government on the quality of analysis supporting new regulations.
Following scrutiny of an impact assessment (IA) carried out prior to a regulatory proposal, the RPC provides an ‘opinion’ on the quality of analysis and evidence presented in the IA. This opinion then informs the decisions of ministers as to whether they proceed or not with the proposal.
Published: 27 August 2014